About Us

Mind Medicine Australia exists to help alleviate the suffering and suicides caused by mental illness in Australia through expanding the treatment options available to medical practitioners and their patients. We will establish safe and effective psychedelic-assisted treatments to treat a range of mental illnesses.

Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses. Our focus is wholly clinical.

Indications of success

• These therapies become an integral part of our Mental Health System
• With high remission rates leading to a substantial improvement in our Mental Health Statistics
• And that these therapies are accessible and affordable to all Australians in need

Four key strategic areas

Mind Medicine Australia acts as a nexus between clinicians, academia, government, regulators, philanthropists, and patients, working in close consultation and partnership with relevant experts and organisations. Our focus includes awareness and knowledge building through education, events, and webinars. We provide a professional development program, including the world-leading Certificate in Psychedelic-Assisted Therapies (CPAT)™ along with other workshops and courses. We support university research, education, funding, and development of clinical trials. We also support patient access, affordable medicine supplies and the development of clinics.

Inclusivity

Mind Medicine Australia is committed to creating a diverse and inclusive environment and is proud to be an equal opportunity employer. All qualified applicants receive consideration for employment without regard to race, colour, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status. Mind Medicine Australia associated practitioners also offer an inclusive and safe place for patients to receive care. We respect and value the cultural differences between us.

Research

We support and fund clinical psychedelic research, conducted by independent institutions and affiliates.

Partnerships

By developing relationships between government, academic institutions, interest groups and regulatory bodies, Mind Medicine Australia aims to facilitate evidence-based change.

Education & Events

We educate the general public, medical and mental health practitioners, regulators, and other stakeholders on clinical psychedelic research and therapeutic application.

Training

Mind Medicine Australia will act as the interface between research and practice by translating clinical research into accredited therapist training protocols, such as with our Certificate in Psychedelic-Assisted Therapies (CPAT)™.

Our achievements in the first 5 years

• Successful sold-out launch event with Professor David Nutt at the University of Melbourne
• Awareness and Knowledge Building including 551,000+ page views on our MMA website
• Established a world-class Board and global network of MMA Ambassadors, Advisory Panel, Young Leaders and Lived Experience Panels 
• An engaged database of over 72,000+ diverse people from a range of sectors and 47,000+ people on our mailing list.
• A national Chapters network of over 30 Chapters and 2200+ engaged clinicians and citizens building grassroots awareness and running education events around Australia and New Zealand
• 230+ webinars including FREE Global Webinar Series with the leaders in the field, numerous documentary screenings and a range of special events attracting 42,000+ participants
• Launched Global Podcast Series, so far featuring 56 podcasts with leaders in psychedelics
• Built relationships with the key academic, professional and regulatory stakeholders nationally and internationally 
• Launched Australia’s first Book of Psychedelic Healing Stories 
• 684,000+ Youtube views and 5371+ subscribers
• 680+ donors   
• 310+ media appearances across Australia’s biggest publications including national news
• Over 101,700+ followers on our social media channels 
• Over 1333+ people trained in psychedelic-assisted therapies across our suite of training programs, including two-day workshop, Certificate of Psychedelic-Assisted Therapies™ with a world class Faculty (recently cited as the world’s leading CPAT™ training globally by Professor David Nutt), online courses and Global Summit. MMA’s training programs have engaged with participants in every State of Australia and more than 15 other nations. Our CPAT™ program is Australia’s first accredited psychedelic training course.
• Held the Southern Hemisphere’s largest and most respected industry event with 30+ world-leading speakers presenting at our International Summit on Psychedelic Therapies for Mental Illness in November 2021
• Over 80,000 visits to the Summit website
• 180+ partner organisations for the Summit
• Involved in funding numerous clinical trials around Australia, including the ANU Registry, an OCD and a healthy persons trials.
• Developed medicine supplies with overseas partners and working on manufacturing of medicines in Australia
• Helped secure $15 million grant from Federal Government towards novel research in Australia through the Medical Research Futures Fund
• Submission of our TGA application to reschedule MDMA and psilocybin from Schedule 9 (Prohibited Substances) to Schedule 8 (Controlled Medicines)
• Australia’s TGA has granted approvals through SAS-B for psilocybin and MDMA-assisted therapies for patients on a case-by-case basis as a result of MMA’s work.
• Developing  a gold standard National Care Program, clinical protocols and standard operating practices for psychedelic-assisted therapies in partnership with leading clinical groups around Australia
• Developed a BLOG, significant education resources and partnered with Universities to disseminate these as well as sharing these via our website
• Submissions made to the Victorian Royal Commission on Mental Health and to the Productivity Commission, other Government departments and presented to hundreds of politicians
• Launch of Mind Medicine Australia’s Patient Support Fund (PSF) supporting 8 patients with a total commitment of $74.000+ in its first year.